Macular Degeneration Treatment Market Analysis, Share, Drivers, Growth 2024-2033: Strategic Examination

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Macular Degeneration Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The macular degeneration treatment market size has grown rapidly in recent years. It will grow from $9.74 billion in 2023 to $10.99 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to aging population, lifestyle changes, limited treatment options, rising awareness, healthcare infrastructure development.

The macular degeneration treatment market size is expected to see rapid growth in the next few years. It will grow to $16.99 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to advancements in research, increased healthcare expenditure, rising incidence rates, personalized medicine approaches, global efforts for vision health. Major trends in the forecast period include focus on neuroprotection and regeneration therapies, expansion of telemedicine and remote monitoring, personalized medicine approaches, investigation of stem cell therapies, patient-focused initiatives for awareness and education.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

Market Segmentation:
The macular degeneration treatment market covered in this report is segmented -
1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD
2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals
3) By Route of Administration: Oral, Injectable, Other Route of Administration
4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Major Driver - Growing Retinal Disorder Incidence Propels Macular Degeneration Treatment Market
The increasing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect the vital tissue and affect the way individuals process visual information, leading to distorted or absent vision. According to the American Academy of Ophthalmology, in 2050, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, a general term used to describe a group of eye disorders, with the highest numbers among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment market.

Competitive Landscape:
Major companies operating in the macular degeneration treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Nidec Pharma Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Valeant Pharmaceuticals, Arrys Therapeutics Inc., Santen Pharmaceuticals, StemCells Inc., Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Rxi Pharmaceuticals, Avita Therapeutics Ltd., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc., NanOcular Ltd., Codiak BioSciences Inc., Nightstar Therapeutics plc

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Top Trend - Innovative Solutions Enhanced Macular Degeneration Treatment
Major companies in the macular degeneration treatment market are focused on developing innovative solutions, such as avacincaptad pegol intravitreal solution, for geographic atrophy, and maximizing their profits in the market. Avacincaptad pegol intravitreal solution is a complement C5 inhibitor for treating geographic atrophy secondary. For instance, in August 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received FDA approval for IZERVAY, an avacincaptad pegol intravitreal solution for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY, a complement C5 inhibitor, demonstrated a statistically significant reduction in GA progression at the 12-month primary endpoint in two Phase 3 clinical trials, with photoreceptor loss slowing as early as six months.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Macular Degeneration Treatment Market Characteristics
3. Macular Degeneration Treatment Market Trends And Strategies
4. Macular Degeneration Treatment Market - Macro Economic Scenario
5. Macular Degeneration Treatment Market Size And Growth
…..
27. Macular Degeneration Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

"About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries."

This release was published on openPR.